Pathobiology of pp32 in Breast Cancer
Abstract
Breast cancers differ from benign breast epithelium through the prominent expression of pp32rl and pp32r2, oncogenic members of the pp32 gene family, in contrast to benign epithelium, which predominantly expresses pp32. The purpose of the study is to confirm and extend these preliminary results, to develop practical means to assay pp32 gene family members in clinical samples, and to determine the clinical significance of their presence. The approved proposal encompassed four broad tasks: 1 characterization of the pp32 expression phenotype of a larger sample of 40 prostatic adenocarcinomas; 2 development of a practical molecular pathology assay for altered pp32 transcripts; 3 adaptation of the assay to paraffin-embedded tissue; and 4 preliminary determination of the clinical utility of pp32rl and pp32r2 expression in prostatic adenocarcinoma. In the course of pursuing this work, we recognized that improved assay methods would yield better results for Task 1. To complete these tasks, it was ultimately necessary to raise, affinity- purify, and characterize antibodies to peptides derived from pp32, pp32rl, and pp32r2. Characterization of these antibodies by Western blot shows that they are sufficiently specific to be employed in panels to distinguish the pp32 forms in breast samples; this work will continue beyond the project period.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2003
- Accession Number
- ADA424101
Entities
People
- Gary R. Pasternack
Organizations
- Johns Hopkins University